This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Factor V [labile factor] deficiency제5인자[불안정]의 결핍 (제오인자불안정인자결핍증)

ItemDetails
A. Classification codesICD-10: D68.2 / Special Copayment Reduction: V009
B. SynonymsParahemophilia, Owren disease, AC globulin deficiency, Proaccelerin deficiency
C. Adult onsetNot low — mild cases may be first discovered in adulthood in situations of hemostatic stress such as surgery and childbirth
1. History2. Causes
3. Genetics4. General epidemiology
5. Pathophysiology6. Symptoms
7. Signs8. Screening
9. Diagnosis10. Treatment
11. Prognosis12. Prevention
13. References

1. History

Paul Owren and the first description of parahemophilia

Factor V (FV) deficiency was first described in 1947 by the Norwegian physician Paul Owren. Owren discovered that a female patient with a severe bleeding tendency was deficient in a new coagulation factor not detected in serum and named it parahemophilia. He explained the absence of FV in serum by the property of 'labile factor (unstable)', which derives from the fact that FV is consumed or degraded during blood clotting and is therefore barely detectable in serum. In the same year, Quick also reported a similar group of patients, but Owren's name gained priority, and it is still called Owren disease today.

Elucidation of the biochemical properties of FV

Subsequently, in the 1950s–60s, the biochemical properties of FV began to be elucidated. Because FV is rapidly inactivated in serum, it was also called 'accelerin' or 'proaccelerin' in the past. In the 1980s–90s, the complete amino acid sequence and domain structure of FV were revealed using recombinant protein technology, and FV was confirmed to be a large protein of 2224 amino acids with a six-domain structure of A1-A2-B-A3-C1-C2.

Discovery of FV Leiden: contrast with deficiency

In 1994, Dahlback et al. discovered a specific variant of the F5 gene (p.Arg506Gln, FV Leiden) in patients with thrombosis who showed resistance to activated protein C (APC). FV Leiden hinders inactivation of FV by APC, so the prothrombinase complex remains continuously activated, and as a result the thrombotic risk increases. This revealed that variants of the same gene, F5, cause opposite phenotypes: deficiency (parahemophilia, bleeding) and excess (FV Leiden, thrombosis). This contrasting concept is key to understanding FV biology.


2. Causes

Congenital causes: F5 gene variants

Congenital FV deficiency (parahemophilia) is caused by pathogenic variants in the F5 gene (chromosome 1q24.2). Reported variant types include missense, nonsense, frameshift and splicing variants, and clinical deficiency appears when they are present in a homozygous or compound heterozygous state. FV is also stored in platelet alpha granules (platelet FV is about 20% of total blood FV), so with some variants plasma FV is reduced but platelet FV is relatively preserved, and the bleeding tendency is sometimes milder than predicted.

Acquired causes

Causes of acquired FV reduction include severe liver failure (reduced synthesis in hepatocytes), disseminated intravascular coagulation (DIC: increased consumption), massive transfusion (dilution) and primary hyperfibrinolysis. Rarely, autoantibodies against FV (FV inhibitor) form and cause acquired FV deficiency. FV inhibitors can develop after transfusion (transfusion-related acquired inhibitors), after surgery, after exposure to antibiotics (especially aminoglycosides) or in the setting of autoimmune disease, and the clinical presentation can be sudden and severe.

Combined FV and FVIII deficiency

Combined FV and FVIII deficiency (F5F8D), in which FV and FVIII are deficient simultaneously, is an independent genetic disease distinct from isolated FV or FVIII deficiency and is caused by a defect in endoplasmic reticulum→Golgi transport due to variants in the LMAN1 or MCFD2 gene. In this combined deficiency, both factors are each reduced to 5–30%, and the bleeding tendency is generally milder than in isolated severe deficiency. When FV deficiency is suspected, it is recommended to measure FVIII as well to check for combined deficiency.


3. Genetics

Structure of the F5 gene

The F5 gene is located on chromosome 1q24.2 and consists of 25 exons. The FV protein is a large protein of about 330 kDa consisting of 2224 amino acids, with the domain structure A1-A2-B-A3-C1-C2. The A and C domains show structural homology with ceruloplasmin, a copper-binding protein. The large B domain (amino acids 709–1545) has an unclear functional role but serves to maintain FV in its inactive form. When thrombin or FXa cleaves the B domain, FV becomes activated FVa.

Domain relationship with APC resistance (FV Leiden)

The FV Leiden variant (p.Arg506Gln) is a point variant at position Arg506, the APC cleavage site for FVa inactivation. APC normally inactivates FVa by sequentially cleaving it at Arg506, Arg306 and Arg679. In FV Leiden, cleavage at Arg506 is impossible, so FVa inactivation is markedly delayed and prothrombinase complex activity persists. This is why it is the most common congenital thrombotic risk factor in populations of European descent. In congenital FV deficiency, in direct contrast to the Leiden variant, FVa itself is lacking, so the prothrombinase complex cannot form sufficiently.

Mode of inheritance and variant distribution

Congenital FV deficiency follows an autosomal recessive inheritance pattern. Heterozygous carriers (FV activity about 50%) are mostly asymptomatic. Clinical symptoms appear in homozygotes or compound heterozygotes when FV activity falls below 10%. The FV Leiden variant (p.Arg506Gln) is at a different gene position from congenital deficiency variants, and when FV Leiden heterozygosity accompanies FV deficiency, inactivation of the residual FVa is also delayed, which can create an interesting clinical situation with a conflicting phenotype.


4. General epidemiology

Prevalence and geographic distribution

The worldwide prevalence of congenital FV deficiency is estimated at about 1 in 1 million. According to registry data from the European Network of Rare Bleeding Disorders (EN-RBD), FV deficiency accounts for about 5–8% of all rare coagulation factor deficiencies. High incidence due to consanguineous marriage is reported in Iran, southern Italy and some Middle Eastern regions. A study conducted in Iran described FV deficiency as the third most common rare coagulation factor deficiency after FXI deficiency and FVII deficiency.

Sex and age

Because it is autosomal recessive, males and females are affected equally. Severe deficiency (FV <1%) presents in the neonatal period or infancy with umbilical cord bleeding and intracranial hemorrhage. In moderate deficiency (FV 1–10%), multiple hematomas and hemarthrosis appear in childhood. In mild deficiency (FV 10–50%), adult patients first discovered at surgery or childbirth are not uncommon. Acquired FV deficiency due to FV inhibitors can occur at any age and is more common in elderly patients with a history of transfusion.

Epidemiology of FV inhibitors

Reported cases of acquired FV inhibitors are limited, but they can cause clinically very serious bleeding. Dozens of cases have been reported in which patients who received topical thrombin sealants (bovine thrombin preparations) after surgery formed antibodies to bovine FV that, through cross-reactivity, inhibited human FV. Today this risk has greatly decreased with the use of human-derived or recombinant thrombin sealants.


5. Pathophysiology

Physiological role of normal FV

FV is the key cofactor of the prothrombinase complex. This complex consists of FXa (catalyst), FVa (cofactor), Ca²⁺ (ionic binder) and phospholipid (activated platelet surface or damaged endothelium), and it amplifies the rate of conversion of prothrombin to thrombin by about 1,000–10,000-fold compared with the reaction of FXa alone without FVa. FVa acts as a 'scaffold' that properly positions FXa and prothrombin on the phospholipid surface. Thus FV plays a decisive role in the amplification phase of explosive thrombin generation in the coagulation response.

Pathophysiology of FV deficiency

When FV is deficient, the prothrombinase complex cannot function normally and thrombin generation is severely reduced. At FV activity below 1%, spontaneous bleeding (intracranial hemorrhage, hemarthrosis, mucosal bleeding) occurs. Even when FV is absent from plasma, some FV is stored in platelet alpha granules, so at sites of local injury where platelets are activated, platelet-derived FV can partially compensate for hemostasis. As a result, the clinical bleeding tendency is sometimes milder than expected even when plasma FV levels are very low. Because FV is located in the common pathway, both PT and aPTT are prolonged.

Understanding through comparison with APC resistance

FV deficiency (parahemophilia) and FV Leiden (APC resistance) arise from abnormalities of the same gene but show completely opposite clinical phenotypes. In FV deficiency, the cofactor of the prothrombinase complex is lacking, so thrombin generation decreases and bleeding occurs. In FV Leiden, inactivation of FVa by APC is blocked, so the prothrombinase complex remains activated for too long and thrombosis occurs. Rarely, when FV Leiden heterozygosity coexists in a patient homozygous for FV deficiency, the residual FVa is difficult to inactivate, and a complex phenotype with a mixed bleeding and thrombotic tendency may appear.


6. Symptoms

Symptoms of severe FV deficiency

In severe deficiency with FV activity below 1%, serious bleeding symptoms occur from the neonatal period. The most typical initial symptom is umbilical cord bleeding, followed by intracranial hemorrhage (ICH), hemarthrosis and intramuscular hematomas. Intracranial hemorrhage is reported to occur in about 10–15% of all FV deficiency cases and is the main cause of death in severe deficiency. Gastrointestinal bleeding, epistaxis and oral mucosal bleeding are also common. In female patients, heavy menstrual bleeding, excessive postpartum bleeding and intrauterine hematoma are characteristic.

Symptoms of moderate and mild deficiency

In moderate deficiency with FV activity of 1–10%, spontaneous bleeding is rare, and excessive bleeding occurs mainly after minor trauma, surgery, dental procedures or childbirth. In mild deficiency with FV activity of 10–50%, there is no or only a mild everyday bleeding tendency, and it is sometimes discovered incidentally in adulthood through simultaneous prolongation of PT and aPTT on preoperative testing. Some mild patients complain of recurrent nosebleeds, gum bleeding and subcutaneous bruising.

Symptoms due to acquired FV inhibitors

When FV inhibitors have formed, symptoms tend to appear suddenly and severely. FV inhibitors should be suspected when extensive bruising, mucosal bleeding or gastrointestinal bleeding suddenly occurs within days to weeks after surgery or transfusion. An acute bleeding tendency in patients with underlying autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis) also suggests the development of FV inhibitors.


7. Signs

Physical examination findings

On physical examination of patients with FV deficiency, various bleeding signs appear depending on severity. In severe deficiency, extensive ecchymoses throughout the body, mucosal bleeding (oral, nasal), and joint swelling and functional limitation are observed. Neurological sequelae after intracranial hemorrhage (hemiplegia, cognitive decline, speech disorder) may be found on physical examination. In patients with FV inhibitors, extensive bruises or hematomas of acute onset are prominent. Because FV is a vitamin K-independent factor, when PT and aPTT are both prolonged in a patient without jaundice or signs of cirrhosis, a differential diagnosis including FV deficiency should be made.

Laboratory abnormalities

The characteristic laboratory finding of FV deficiency is simultaneous prolongation of PT and aPTT. PT reflects common pathway abnormalities downstream of the FVIIa-TF complex of the extrinsic pathway, and aPTT reflects common pathway abnormalities downstream of the intrinsic pathway. TT and fibrinogen are normal, distinguishing it from FI deficiency. If PT·aPTT corrects with normal plasma in the mixing test, FV deficiency is likely. The diagnosis is confirmed by demonstrating reduced FV activity on an FV-specific factor assay. Vitamin K is normal (FV is vitamin K-independent), which is a point of differentiation from FVII, FIX and FX.

Platelet function tests

In some patients with FV deficiency, intraplatelet FV (FV stored in platelet alpha granules) levels are also reduced, which appears on whole-blood viscoelastic tests (TEG, ROTEM) as delayed initiation of fibrin formation and reduced clot strength. Prolonged clotting time (CT) is observed in both the EXTEM and INTEM assays of ROTEM. Platelet aggregation testing (PRP aggregation test) generally shows no abnormal findings with FV deficiency alone, but in patients whose intraplatelet FV storage is also deficient, partial platelet dysfunction may appear.


8. Screening

Interpretation of simultaneous PT and aPTT prolongation

The key to screening for FV deficiency is when PT and aPTT are prolonged simultaneously while TT and fibrinogen are normal. This pattern suggests deficiency of one or more factors of the common coagulation pathway (FI, FII, FV, FX). When vitamin K deficiency or warfarin administration has been excluded (the possibility of deficiency of vitamin K-dependent factors such as FVII, FIX and FX must be excluded), FV deficiency is included in the differential diagnosis after excluding liver failure and DIC. Care in specimen handling is needed: FV is unstable in plasma, so testing must be completed soon after blood collection (preferably within 4 hours, stored at 4°C).

Mixing test

When PT·aPTT prolongation is confirmed, patient plasma is mixed 1:1 with normal pooled plasma (NPP) and remeasured immediately. If the prolongation is due to deficiency, PT·aPTT corrects to normal or near normal after mixing. Failure to correct suggests an inhibitor (including FV inhibitors) or lupus anticoagulant. When an FV inhibitor is suspected, the inhibitor titer (BU, Bethesda unit) is quantified using the Bethesda method, which remeasures after 2 hours of incubation at 37°C.

Specific FV factor assay and platelet FV measurement

When correction occurs in the mixing test, an FV-specific factor assay is performed. FV activity is measured by a PT-based clotting assay using FV-deficient substrate plasma. When the degree of clinical bleeding is milder than expected despite low plasma FV levels, platelet FV measurement can be considered. Methods that wash and lyse platelets to measure FV antigen or activity are used in research, and whether platelet FV is preserved can affect treatment decisions.


9. Diagnosis

Diagnostic criteria

Congenital FV deficiency is confirmed in the following order: ① simultaneous prolongation of PT and aPTT, ② reduced FV activity on FV-specific factor assay (severe: <1%, moderate: 1–10%, mild: 10–50%), ③ normal vitamin K-dependent factors (FVII, FIX, FX) and exclusion of vitamin K deficiency, ④ exclusion of acquired causes such as DIC and liver failure, and ⑤ genetic analysis (identification of a pathogenic variant in the F5 gene). The diagnosis of acquired FV inhibitors is confirmed by Bethesda inhibitor quantification.

Differential diagnosis

The differential diagnosis of simultaneous PT and aPTT prolongation is as follows: ① vitamin K deficiency or warfarin (FII, FVII, FIX and FX all reduced, FV normal), ② FX deficiency (FV normal, FX reduced), ③ FII deficiency (FV normal, FII reduced), ④ fibrinogen deficiency (TT prolonged, fibrinogen reduced), ⑤ combined FV+FVIII deficiency (both factors reduced to 5–30%), and ⑥ DIC (thrombocytopenia, elevated D-dimer, reduction of multiple factors). When simultaneous FV and FVIII deficiency is confirmed, combined deficiency is confirmed by LMAN1/MCFD2 gene analysis.

Genetic counseling

Because it is autosomal recessive, when both parents are heterozygous carriers, homozygous deficiency can occur in 25% of their children. FV activity testing is recommended for the siblings and both parents of confirmed patients. FV Leiden carrier status is also checked during genetic counseling to discuss the possibility of a combined FV deficiency + FV Leiden phenotype. For patients planning pregnancy, preimplantation genetic diagnosis (PGT) or prenatal testing is considered.


10. Treatment

Fresh frozen plasma (FFP): the only realistic option

The key limitation in treating FV deficiency is that there is no commercial concentrate of FV. Therefore, the most widely used treatment at present is fresh frozen plasma (FFP). FFP contains all plasma coagulation factors and is the only external source of FV. The target FV level is 15–25% during acute bleeding and 20–25% during surgery, and 15–20 mL/kg of FFP is needed to achieve this. FFP administration carries risks of volume overload, allergic reactions, transfusion-related acute lung injury (TRALI) and transfusion-transmitted infection.

Platelet transfusion

Because about 20% of total blood FV is stored in platelet alpha granules, platelet transfusion can be used as an adjunct to or sole alternative to FFP. Platelet transfusion is particularly useful when bleeding persists despite FFP administration or when intraplatelet FV is also deficient. Platelet transfusion exerts a hemostatic effect because FVa on the surface of platelets activated at the site of local injury contributes directly to the prothrombinase complex. However, there is a risk of alloantibody formation, so caution is needed with long-term repeated transfusion.

Treatment of acquired FV inhibitors

When FV inhibitors are confirmed, the two goals of bleeding control and inhibitor eradication must be pursued simultaneously. FFP and platelets are given to achieve hemostasis of acute bleeding, taking into account that the administered FV can be rapidly neutralized by the inhibitor. When the inhibitor titer is low (BU <5), a strategy of saturation with high-dose FFP is also used. To eradicate the inhibitor, immunosuppressive therapy (prednisolone, cyclophosphamide, rituximab) is given, and plasmapheresis is sometimes used to lower the titer rapidly. Recombinant FVIIa can be expected to have a hemostatic effect that bypasses FV and is used for bleeding management in patients with FV inhibitors.


11. Prognosis

Prognosis of severe deficiency

In severe FV deficiency (FV <1%), if the diagnosis is not made before intracranial hemorrhage occurs, the risk of neurological sequelae or death is high. Long-term survival is improving as regular prophylaxis with FFP has become possible, but there is the practical limitation that the half-life of FFP (FV half-life about 12–36 hours) is short and frequent administration is needed. With recurrent hemarthrosis, progression of arthropathy can cause long-term functional limitation.

Prognosis of mild and moderate deficiency

Patients with FV activity in the 1–50% range can maintain a quality of life almost equivalent to the general population with appropriate preoperative management and regular follow-up. In female patients, establishing a plan for FFP supply before delivery during pregnancy can minimize obstetric complications. Thrombosis complicating FV deficiency is very rare, but it should be recognized that in patients with a combined FV Leiden variant there is theoretically a combined thrombosis-bleeding risk.

Prognosis of acquired FV inhibitors

In acquired FV inhibitors that respond to immunosuppressive treatment, the inhibitor often disappears completely, and the long-term prognosis is relatively good. However, when there is no response to immunosuppressive treatment or the inhibitor titer is very high, there is a risk of death from serious bleeding.


12. Prevention

Prophylactic FFP administration and practical limitations

In severe FV deficiency, an approach of preventing spontaneous bleeding with prophylactic FFP administration is recommended, but there are several limitations in practice. Because the FV half-life (about 12–36 hours) is short, FFP administration is needed every 2–3 days, and repeated large-volume FFP administration carries a risk of volume overload. For this reason, whether to give prophylaxis and at what interval are decided individually in patients with severe FV deficiency. Prophylactic FFP once every 2–3 weeks is somewhat effective in preventing everyday spontaneous bleeding, but additional administration is always needed for trauma or surgery.

Preoperative planning

Before surgery, FV activity is measured, the FFP dose needed to achieve the target level (20–25%) according to the scale of surgery is calculated, and it is given immediately before surgery. Real-time coagulation monitoring with viscoelastic coagulation tests (ROTEM, TEG) during surgery is recommended. When there is concern about minor bleeding, tranexamic acid can be used as adjunctive therapy (it inhibits fibrin degradation and stabilizes the formed clot). Before dental procedures, using an antifibrinolytic (tranexamic acid) as a mouth rinse is helpful.

Lifestyle guidance and genetic counseling

Patients with FV deficiency are advised to refrain from physical activities with a high bleeding risk (combat sports, contact sports). They are educated to wear protective equipment during activities with a risk of trauma, to disclose their history of coagulation factor deficiency when visiting a new medical facility, and to avoid nonprescription NSAIDs and aspirin. Through genetic counseling, testing of siblings and children is recommended, and when pregnancy is planned, information on genetic counseling and the possibility of prenatal diagnosis is provided. FV Leiden variant carrier status is checked and used as a reference for predicting the phenotype.


13. References

  1. Owren PA. Parahemophilia: hemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet. 1947;1(6460):446-448.
  2. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90(3):1004-1008.
  3. Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012;10(4):615-621.
  4. Bhatt MD, Bhatt A, Bhatt RD. Factor V deficiency: a review. Blood Rev. 2020;44:100710.
  5. Lak M, Sharifian R, Peyvandi F, Mannucci PM. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol. 1998;103(4):1067-1069.
  6. Kane WH, Davie EW. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood. 1988;71(3):539-555.
  7. Yang TL, Pipe SW, Yang A, Ginsburg D. Biosynthetic origin and functional significance of murine platelet factor V. Blood. 2003;102(8):2851-2855.
  8. Seligsohn U, Zivelin A, Zwang E. Combined factor V and factor VIII deficiency among non-Ashkenazi Jews. N Engl J Med. 1982;307(18):1191-1195.
  9. Trossaert M, Regnault V, Sigaud M, et al. Mild factor V deficiency with FV Leiden: what is the clinical significance? J Thromb Haemost. 2008;6(12):2165-2168.
  10. Zehnder JL, Leung LLK. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood. 1990;76(10):2011-2016.
  11. Huang JN, Koerper MA. Factor V deficiency: a concise review. Haemophilia. 2008;14(6):1164-1169.
  12. Mumford AD, Ackroyd S, Alikhan R, et al. Guideline for the diagnosis and management of the rare coagulation disorders. Br J Haematol. 2014;167(3):304-326.